Your browser doesn't support javascript.
loading
Sorafenib in renal cell carcinoma
Pakistan Journal of Pharmaceutical Sciences. 2014; 27 (1): 203-208
in English | IMEMR | ID: emr-143002
ABSTRACT
Cancer is among most important causes of death in recent decades. Whoever the renal cell carcinoma incidence is low but it seems it is more complicated than the other cancers in terms of pathophysiology and treatments. The purpose of this work is to provide an overview and also deeper insight to renal cell carcinoma and the steps which have been taken to reach more specific treatment and target therapy, in this type of cancer by developing most effective agents such as Sorafenib. To achieve this goal hundreds of research paper and published work has been overviewed and due to limitation of space in a paper just focus in most important points on renal cell carcinoma, treatment of RCC and clinical development of Sorafenib. The information presented this paper shows the advanced of human knowledge to provide more efficient drug in treatment of some complicated cancer such as RCC in promising much better future to fight killing disease.
Subject(s)
Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Carcinoma, Renal Cell / Clinical Trials as Topic / Niacinamide / Receptors, Vascular Endothelial Growth Factor / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Humans Language: English Journal: Pak. J. Pharm. Sci. Year: 2014

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: IMEMR (Eastern Mediterranean) Main subject: Carcinoma, Renal Cell / Clinical Trials as Topic / Niacinamide / Receptors, Vascular Endothelial Growth Factor / Protein Kinase Inhibitors / Antineoplastic Agents Limits: Humans Language: English Journal: Pak. J. Pharm. Sci. Year: 2014